Enlivex (ENLV) Operating Leases (2019 - 2025)
Enlivex (ENLV) posted quarterly Operating Leases of $383000.0 for Q4 2025, up 28.09% year-over-year from $299000.0 in Q4 2024, and up 28.09% quarter-over-quarter from $299000.0 in Q4 2024.
Enlivex (ENLV) Operating Leases (2019 - 2025) Analysis & Trends
Enlivex's Operating Leases history runs 5 years deep, the most recent figure standing at $383000.0 for Q4 2025.
- In Q4 2025, Operating Leases rose 28.09% year-over-year to $383000.0; the TTM figure through Dec 2025 stood at $383000.0 (up 28.09% YoY), while the FY2025 annual figure was $383000.0, up 28.09% from the prior year.
- Operating Leases for Q4 2025 stood at $383000.0, up from $299000.0 in the prior quarter.
- The five-year high for Operating Leases was $5.4 million in Q4 2021, with the low at $299000.0 in Q4 2024.
- The 3-year median for Operating Leases is $383000.0 (2025), against an average of $2.0 million.
- The sharpest annual moves came in 2021 and 2025: Operating Leases surged 979.96% in 2021, then grew 28.09% in 2025.
- Enlivex's Operating Leases stood at $5.4 million in 2021, then slumped by 94.45% to $299000.0 in 2024, then rose by 28.09% to $383000.0 in 2025.
- Business Quant data shows ENLV's Operating Leases at $383000.0 in Q4 2025, $299000.0 in Q4 2024, and $5.4 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Enlivex | 4.58 Mn | -1.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 383,000.00 |
| Dec 31, 2024 | 299,000.00 |
| Dec 31, 2021 | 5.39 Mn |
| Dec 31, 2020 | 499,000.00 |
| Sep 30, 2020 | 499,000.00 |
| Jun 30, 2020 | 236,000.00 |
| Dec 31, 2019 | 298,000.00 |